Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Accured Expenses (2023 - 2025)

Bioregenx's Change in Accured Expenses history spans 3 years, with the latest figure at $53771.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $53771.0 for Q4 2025, up 47.68% from a year ago — trailing twelve months through Dec 2025 was -$18590.0 (down 131.15% YoY), and the annual figure for FY2025 was -$18590.0, down 131.15%.
  • Change in Accured Expenses for Q4 2025 was $53771.0 at Bioregenx, up from -$24896.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $94924.0 in Q2 2023 to a low of -$136984.0 in Q4 2023.
  • The 3-year median for Change in Accured Expenses is $29022.0 (2023), against an average of $4018.8.
  • Peak annual rise in Change in Accured Expenses hit 251.04% in 2025, while the deepest fall reached 406.31% in 2025.
  • Year by year, Change in Accured Expenses stood at -$136984.0 in 2023, then soared by 126.58% to $36410.0 in 2024, then skyrocketed by 47.68% to $53771.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $53771.0, -$24896.0, and -$109036.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.